![Incyte Corp](/common/images/company/L_0J9P.png)
Incyte Corp and Novartis AG on Monday said a phase 3 study of ruxolitinib in Covid-19 patients failed to meet its pri ...
The following is a round-up of updates by global companies, issued on Thursday and Friday and not separately reported ...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 66.79 | 66.79 | 66.79 | 1141 | 66.79 | DE |
4 | 0 | 0 | 66.79 | 66.79 | 66.79 | 1764 | 66.79 | DE |
12 | 0 | 0 | 66.79 | 66.79 | 66.79 | 3615 | 66.79 | DE |
26 | 0 | 0 | 66.79 | 66.79 | 66.79 | 2228 | 66.79 | DE |
52 | 0 | 0 | 66.79 | 66.79 | 66.79 | 1828 | 66.79 | DE |
156 | 0 | 0 | 66.79 | 66.79 | 66.79 | 5375 | 66.79 | DE |
260 | 0 | 0 | 66.79 | 66.79 | 66.79 | 4095 | 66.79 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales